<DOC>
	<DOCNO>NCT01391884</DOCNO>
	<brief_summary>The prevalence type 2 diabetes ( T2D ) increase rapidly worldwide . T2D characterize severely impaired incretin effect . The incretin effect refers insulinotropic action nutrient-released incretin hormone glucagon-like peptide-1 ( GLP-1 ) glucose-dependent insulinotropic peptide ( GIP ) . The incretin effect define difference insulin secretory responses oral isoglycaemic intravenous glucose challenge ( OGTT IIGI , respectively ) healthy individual account much 70 % insulin response follow oral glucose , whereas patient T2D exhibit incretin effect range 0 30 % . Patients T2D non-diabetic patient severe kidney failure share several pathophysiological characteristic , include decreased insulin sensitivity , fast hyperinsulinaemia impair beta-cell function . The reason finding remain fully elucidate . An ongoing study research group investigate incretin effect incretin hormone secretory response follow OGTT , IIGI meal ingestion , respectively . In continuation study , essential knowledge metabolism incretin hormone uremic milieu obtain present study prior evaluation use incretin-based agent patient impaired kidney function . In second study evaluate elimination biodegradation GLP-1 GIP . The biological active incretin hormone rapidly degrade ubiquitous enzyme dipeptidyl peptidase-4 ( DPP-4 ) , generate inactive metabolite . The active hormone however also eliminate renal clearance , although importance remain questionable . It likely degradation elimination active hormone significantly affect patient severe kidney impairment . We hypothesize elimination biodegradation two incretin hormone , itÂ´s active inactive form , affect non-diabetic patient severe kidney failure .</brief_summary>
	<brief_title>Elimination Incretin Hormones Patients With Severe Kidney Failure</brief_title>
	<detailed_description />
	<mesh_term>Uremia</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>1 ) Male female ; age 1890 year CKD stage 5 chronic maintenance dialysis treatment BMI : 18,528 kg/m2 Normal fast plasma glucose ( &lt; 6,1 mM ) Normal impair glucose tolerance ( PG120 min &lt; 11,1 mM follow OGTT ) Male female ; age 1890 year Healthy include normal kidney function BMI : 18,528 kg/m2 Normal fast plasma glucose ( &lt; 6,1 mM ) Normal impair glucose tolerance ( PG120 min &lt; 11,1 mM follow OGTT ) 1+2 ) Diabetes mellitus Chronic pancreatitis / previous acute pancreatitis Treatment oral glucocorticoid , calcineurin inhibitor , thiazide , dipeptidyl peptidase 4 ( DPP4 ) inhibitor drug , could interfere glucose lipid metabolism Inflammatory bowel disease Malignant disease Bowel resection Severe anemia ( hemoglobin &lt; 6.5 mmol/L )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Incretin hormone</keyword>
	<keyword>GLP-1</keyword>
	<keyword>GIP</keyword>
	<keyword>Uremia</keyword>
	<keyword>Dialysis</keyword>
</DOC>